The Time Has Come: 4 Gene Therapy Stocks to Buy, 1 to Avoid – Barron's

This post was originally published on this site

It’s a big day for gene therapy. A panel of independent FDA advisors is meeting today to consider the merits of Luxturna, a one-time gene therapy developed by Spark Therapeutics (ONCE) meant to treat a rare form of childhood blindness.

If the panel votes to recommend the drug’s approval, and the FDA follows that recommendation (as the agency usually does), Spark’s drug becomes the first therapy meant to replace or repair a defective gene approved in the U.S.